To include your compound in the COVID-19 Resource Center, submit it here.

FluInsure intranasal vaccine: IDBE will begin this month a double-blind, placebo-controlled Phase II trial in Canada of its FluInsure intranasal vaccine to prev

ID Biomedical Corp. (IDBE; TSE:IDB), Vancouver, B.C.
Product:

Read the full 84 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE